DNAtrix To Present Interim Phase 2 Results of DNX-2401 with Pembrolizumab for Glioblastoma

Thursday, November 15, 2018 Cancer News
Email Print This Page Comment bookmark
Font : A-A+

--Multiple Studies of DNAtrix Oncolytic Viruses to be Presented at the SNO Annual Meeting--

HOUSTON, Nov. 15, 2018 /PRNewswire/ -- DNAtrix, a leader in oncolytic virus immunotherapies for cancer, will present

interim results from the ongoing Phase 2 trial of its oncolytic virus DNX-2401 (tasadenoturev) with pembrolizumab for patients with recurrent glioblastoma at the upcoming 2018 Annual Meeting of the Society for Neuro-Oncology (SNO) which is being held in New Orleans, Louisiana from November 15th - 18th.

CAPTIVE / KEYNOTE-192 is a Phase 2 multicenter, dose escalation study evaluating a single intratumoral injection of DNX-2401 followed by standard dosing with pembrolizumab every three weeks to determine the optimal dose, safety, and efficacy in patients with recurrent glioblastoma. Preliminary results demonstrate that DNX-2401 with pembrolizumab is well tolerated, and associated with promising survival.

"I am excited by the early results of the trial. We have had some very remarkable responses.  If I had not done the case myself, I would not have believed the complete response we have seen in one of our patients," said Gelareh Zadeh, MD, Associate Professor at the Department of Surgery University of Toronto, and presenting author for the CAPTIVE / KEYNOTE-192 study.

"There are limited treatment options for patients with this devastating disease, and we are encouraged by the initial data showing safety and disease control with the combination of DNX-2401 and pembrolizumab," added Frank Tufaro, PhD, CEO of DNAtrix. "We are pleased that enrollment is nearly complete and we are looking forward to maturation of the survival data."

DNAtrix collaborators will present additional results from studies of DNX-2401 (a.k.a. Delta-24-RGD) and murine DNX-2440 (a.k.a. Delta-24-RGDOX), an oncolytic adenovirus expressing the immune modulator OX40 ligand.  Details of the presentations are as follows:

Interim results of a phase II multicenter study of the conditionally replicative oncolytic adenovirus DNX-2401 with pembrolizumab (Keytruda) for recurrent glioblastoma; CAPTIVE Study (KEYNOTE-192)Date: Saturday, November 17Abstract Number: ATIM-24Presenter: Gelareh Zadeh, MD, University Health Network, University of Toronto, Toronto, ON, CanadaTo access the abstract, click here >

Inflammatory reprogramming of gliomas using Delta-24-RGDOX and immunometabolic adjuvantsDate: Friday, November 16Abstract Number: EXTH-27Presenter: Teresa Nguyen, The University of Texas MD Anderson Cancer Center, Houston, TX, USATo access the abstract, click here >

Local oncolytic adenovirus treatment affects both the innate and adaptive arms of the immune system and provides an avenue for enhancing immunotherapies for GBMDate: Friday, November 16Abstract Number: EXTH-03Presenter: Martine Lamfers, PhD, Erasmus Medical Center, Rotterdam, NetherlandsTo access the abstract, click here >

In Situ Autovaccination Mediated by Oncolytic Adenovirus Delta-24-RGDOX Induces Efficacious Immunity Against Metastatic MelanomaDate: Saturday, November 17Abstract Number: EXTH-30Presenter: Hong Jiang, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, USATo access the abstract, click here >

Delta-24-RGD in combination with positive regulators of the immune synapsis for gliomas in adults and childrenDate: Sunday, November 18Oral Presentation: Juan Fueyo, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

For more information about ongoing DNAtrix clinical studies, visit the ClinicalTrials.gov website: NCT02798406 (DNX-2401 + pembrolizumab for recurrent glioblastoma), NCT03178032 (DNX-2401 for newly diagnosed pediatric diffuse intrinsic pontine glioma, DIPG), and NCT03714334 (DNX-2440 for recurrent glioblastoma).

About DNX-2401 (Tasadenoturev)DNX-2401 is an investigational oncolytic immunotherapy designed to treat cancer. DNX-2401 sets off a chain reaction of tumor cell killing by selectively replicating within cancer cells (but not normal cells), causing tumor destruction and further spread of the oncolytic virus to adjacent tumor cells. This process then triggers an immune response directed against the tumor. Previous studies demonstrated that DNX-2401 was well tolerated, provided clinical benefit, and extended survival for patients with recurrent glioblastoma.

About DNAtrixDNAtrix is a privately held, clinical stage, biopharmaceutical company developing oncolytic virus immunotherapies for cancer. Its oncolytic adenovirus platform viruses initiate a chain reaction of tumor cell killing by selectively replicating within cancer cells (but not normal cells), triggering an immune response directed against tumors.  DNAtrix has multiple virus candidates in clinical trials for cancers with urgent needs for novel approaches. For more information, please visit the company website at www.DNAtrix.com.

Contact                  DNAtrixImran Alibhai, PhDSVP Business Developmentialibhai@dnatrix.com


Cision View original content:http://www.prnewswire.com/news-releases/dnatrix-to-present-interim-phase-2-results-of-dnx-2401-with-pembrolizumab-for-glioblastoma-300751011.html


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store